在老年人中治疗心房动
Anna L Parks1, David S Frankel2, Dae H Kim3
1University of Utah, Division of Hematology and Hematologic Malignancies, Salt Lake City, UT, USA.
概括
这次审查强调,由于衰老的复杂性,标准的心房动治疗可能不适合所有老年人. 个性化,以衰老为重点的方法对于老年人有效的心房动管理至关重要.
科学领域:
- 老年学和老年医学是老年学和老年医学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心房动通常会影响老年人,经常伴随多种慢性疾病和多药.
- 当前心房的指导方针和临床试验经常采用年龄不可知的方法.
- 衰老的异质性需要为心房动的老年人制定量身定制的治疗策略.
研究的目的:
- 通过老龄化科学的透视来综合关于心房动管理的证据.
- 将并发症和老年综合征对老年人中心房的护理的影响置于背景.
- 为心房管理提出一个以衰老为重点的框架,优先考虑患者的目标.
主要方法:
- 综合综合现有关于老年人心房的证据的综合文献综述.
- 应用衰老科学原则来评估心房的标准管理支柱.
- 在心房的背景下分析并发症,老年综合征和多药学.
主要成果:
- 患有心房的老年人面临着独特的挑战,包括并发症和老年综合征.
- 标准的心房动管理需要适应,以考虑到个体的衰老轨迹.
- 一个以衰老为重点的框架可以指导各种老年人群的个性化治疗决策.
结论:
- 在老年人中心房的管理需要个性化的方法,超越了不依赖年龄的指导方针.
- 整合衰老科学原则对于优化查,生活方式干预和治疗策略至关重要.
- 以患者为中心的框架优先考虑目标,确保为所有心房动的老年人提供基于证据的护理.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Disturbances in Heart Rhythm
916
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
916
Decreased pulse rate
535
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
535
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
718
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
718
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
791
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
791
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396


